Biogen Inc. (BIIB) Stifel 2026 Virtual CNS Forum March 18, 2026 9:30 AM EDT
Company Participants
Diana Gallagher – Head of AD, MS & Immunology Development Units
Stephanie Melillo Fradette
Conference Call Participants
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Paul Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division
Great. Thanks very much. This is going to be an interesting 45-minute discussion on a number of topics within the Biogen pipeline. With me is Diana Gallagher, Head of Clinical Development; and Stephanie Fradette, Head of the Neuromuscular Development Unit. Maybe just you can each of you just sort of briefly introduce yourselves, how long you’ve been at Biogen, and then we can get right into it. I think I wanted to start with maybe talking about tau, but we can cover a lot of stuff. So Diana, do you want to go first?
Diana Gallagher
Head of AD, MS & Immunology Development Units
Sure. Thanks for having us, Paul. So my name is Diana Gallagher. I have several of the therapeutic areas of Biogen, so the Alzheimer’s, the MS and the immunology portfolios, and I’ve been at Biogen almost 11 years this month, yes.
Paul Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division
Awesome.
Stephanie Melillo Fradette
And Steph Fradette, again, thank you. Thank you for having us. I lead our neuromuscular development unit, and I’ve essentially been at Biogen for the last 16 years, believe it or not, and really focused on our neuromuscular efforts for over the past decade.
Question-and-Answer Session
Paul Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division
Okay. Awesome. All right. Well, great to talk to you both of you, and thank you both for taking the time. So yes, so I’m super interested in this tau readout. I have followed this space for a while. We were always somewhat skeptical on
